



ASX / Media Release

23 March 2026

Resignation of Joint Company Secretary

Invex Therapeutics Limited (**Invex, ASX:IXC, or the Company**) gives notice that, in accordance with ASX Listing Rule 3.16.1, Ms Carla Healy resigns as Joint Company Secretary effective 23 March 2026. We thank Ms Healy for her contribution to the Company and wish her all the best with her future endeavours.

Mr Tim Slate remains Company Secretary and is the person responsible for communications between the Company and ASX under Listing Rule 12.

- ENDS -

This release dated 23 March 2026 has been authorised for lodgement to ASX by the Board of Invex Therapeutics Ltd.

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.